Search

Displaying results 9241 - 9250 of 10000 in total
  1. Drug

    Cadisegliatin

    go.drugbank.com/drugs/DB18886
    Investigational

    Cadisegliatin is under investigation in clinical trial NCT06334133 (Cadisegliatin as Adjunctive Therapy in Type 1 Diabetes).

  2. Drug

    FX06

    go.drugbank.com/drugs/DB05685
    Investigational

    FX06 is a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bbeta(15-42)). It prevents leukocyte migration through the gap junctions of endothelial cells.

  3. Drug

    Epirizole

    go.drugbank.com/drugs/DB08991
    Experimental

    Epirizole is an oral nonsteroidal anti-inflammatory drug (NSAID) used for muscle and joint pain.

  4. Drug

    NC-6300

    go.drugbank.com/drugs/DB17341
    Experimental

    NC-6300, also known as K-912, is a novel [epirubicin] drug-conjugated polymeric micelle.

  5. Drug

    P-BCMA-101

    go.drugbank.com/drugs/DB17371
    Investigational

    P-BCMA-101 is an autologous CAR-T therapy developed using Poseida’s piggyBac platform technology.

  6. Drug

    AAV-RPE65

    go.drugbank.com/drugs/DB18343
    Experimental

    AAV-RPE65 is an adenovirus associated viral vector serotype 5 containing the human RPE65 gene

  7. Drug

    Descartes-30

    go.drugbank.com/drugs/DB16361
    Investigational

    Descartes-30 is an RNA-engineered off-the-shelf allogeneic mesenchymal stem cell (MSC) product developed by Cartesian Therapeutics. … [L27531] The RNA-engineering is performed with Cartesian Therapeutics’ proprietary RNA Armory which is a platform that activates and provides cells with mRNA-based therapeutics.

  8. Drug

    Alferminogene tadenovec

    go.drugbank.com/drugs/DB05306
    Investigational

    Alferminogene tadenovec represents a new therapeutic class of biologics designed to promote angiogenesis and thereby improve blood flow following a one-time intracoronary administration from a standard … Alferminogene tadenovec, Cardium’s lead product candidate, is being developed for the potential treatment of myocardial ischemia that gives rise to angina symptoms associated with coronary heart disease

  9. Drug

    2-(1-(1-(2-chlorophenyl)-2-methoxy-2-oxoethyl)-4-sulfanyl-3-piperidinylidene) acetic acid

    go.drugbank.com/drugs/DB19221
    Investigational

    2-(1-(1-(2-chlorophenyl)-2-methoxy-2-oxoethyl)-4-sulfanyl-3-piperidinylidene) acetic acid is under investigation in clinical trial NCT03774394 (Impact of Chronic Kidney Disease on Clopidogrel Effects in

  10. Drug

    IMM-0306

    go.drugbank.com/drugs/DB19309
    Investigational

    IMM-0306 (bispecific antibody-trap selectively targeting cd47 and cd20) is under investigation in clinical trial NCT05805943 (Study of IMM0306 in Patients With Relapsed or Refractory Cd20-positive B-cell